839 results on '"Andritsos, Leslie"'
Search Results
2. Hairy Cell Leukemia: Where Are We in 2023?
3. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
4. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
5. Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia
6. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
7. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
8. Hematopoietic Stem Cell Transplantation for Psoriasis and Pemphigus Vulgaris
9. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients
10. Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization
11. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
12. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia
13. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas
14. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
15. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
16. Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
17. Data from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
18. Suppl Table 2 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
19. Suppl Figure 1 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
20. Supplemental Methods from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
21. Suppl Table 1 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
22. Suppl Figure 2 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
23. PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
24. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
25. Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis
26. Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
27. Supplementary Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
28. Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis
29. Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease
30. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
31. Historical overview of hairy cell leukemia
32. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
33. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
34. Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma
35. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells
36. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
37. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
38. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
39. Ibrutinib treatment improves T cell number and function in CLL patients
40. Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]
41. Development of a distributed international patient data registry for hairy cell leukemia
42. Hematopoietic Progenitor Cell Transplantation for Treatment of Chronic Lymphocytic Leukemia
43. Hairy cell leukemia: Update on molecular profiling and therapeutic advances
44. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
45. PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
46. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
47. A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
48. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing
49. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
50. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.